Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

职业发展

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

教育

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

语言

奖励

JUVE Awards 2023

Featured

最新新闻和观点

View Irina's insights

点击此处了解更多

酒店与休闲

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

2024年7月18日

作者 Irina Rebin

酒店与休闲

R&D Collaborations | Coffee Break Life Sciences Start-ups #4

2024年4月18日

In-depth analysis

作者 Irina Rebin

点击此处了解更多

酒店与休闲

Germany as a location for pharmaceutical businesses - quo vadis, 2024?

Strategy paper by the German Federal Government on improving the regulatory framework for the pharmaceutical industry in Germany

2024年1月11日

In-depth analysis

作者 Irina Rebin

点击此处了解更多

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

Related news & insights

Preliminary injunctions in Poland

From small island to big impact: what Vanuatu's ICJ climate win means for business

Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability

AI disputes in action

When intelligent systems fail: a case study in AI liability and the future of commercial disputes

EU Deforestation Regulation (EUDR) – Proposed amendments to reduce bureaucratic burden

Draft Bill on the Implementation of the EU Environmental Criminal Law Directive

EU Parliament rejects trilogue negotiations on the Omnibus Package

Amendment of the CBAM Regulation: Simplifications and Exemptions for Companies

German Batteries Implementation Act and the Automotive Industry – Essential Insights (Part 2) | TWheel

相关人员

与我会面：